Clinical trial · Interventional
Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction
Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction: A Randomized Controlled Trial
NCT04347122CI-TRIAL-00090000terminatedPhase 4Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): recruitment stalled
Summary
Brief summary (as posted)
This study intends to determine if any correlation exists between administration of TXA or not to musculoskeletal oncology patients undergoing endoprosthetic reconstruction and blood loss and blood transfusion rates.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Musculoskeletal Cancer | Sarcoma | PROBABILISTIC | 0.70 |
| Sarcoma,Soft Tissue | Soft Tissue Sarcoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Tranexamic Acid (TXA) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- ACTIVE_COMPARATOR
- label
- Bony tumor treated with Tranexamic acid (TXA)
- description
- This group of participants will undergo a bony tumor resection of the femur or proximal tibia and endoprosthetic reconstruction with TXA.
- interventionNames
- Drug: Tranexamic Acid (TXA)
- type
- NO_INTERVENTION
- label
- Bony tumor treated without TXA
- description
- This group of participants will undergo a bony tumor resection of the femur of proximal tibia and endoprosthetic reconstruction.
- type
- ACTIVE_COMPARATOR
- label
- Soft tissue sarcoma treated with Tranexamic Acid (TXA)
- description
- This group of participants will undergo soft tissue sarcoma resection of the lower extremity with TXA
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Patients undergoing wide resection of a malignant bony tumor of the lower extremity with endoprosthetic reconstruction. * Patients undergoing a resection of soft tissue sarcoma measuring \> 5cm. Exclusion Criteria: * Patients undergoing revision endoprosthetic reconstruction * Patients with known coagulopathy * Known history of DVT or embolic disease * Benign tumors * Patients with allergy to TXA * Those refusing blood products * Those concurrently on anti-coagulant therapy * Pregnant and/or nursing women * Vulnerable populations as defined by the KUMC IRB
References
Publications (0)
Data not yet available
No reference posted for this study.